Antibody optimization has traditionally meant trading one property for another. Gaining affinity comes at the cost of developability or improving humanness detracts from stability. ConvergeAB reframes this as a single specification task: defining a target profile across developability properties, affinity, selectivity, and functionality and then engineering toward all parameters in a single pass. In this session, we present case studies that test the boundaries of this approach, including engineering a biobetter of Cetuximab, building species cross-reactivity, and executing selective affinity maturation against a challenging target. These capabilities are delivered through a secure, accessible platform built for scientists with both non-computational and technical backgrounds.